US · DMAC
DiaMedica Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Minneapolis, MN 55447
- Website
- diamedica.com
Price · as of 2024-12-31
$6.18
Market cap 414.02M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $17.56 | ||||
| 2013 | $16.64 | ||||
| 2014 | $1.60 | ||||
| 2015 | $2.22 | ||||
| 2016 | $2.99 | ||||
| 2017 | $6.21 | ||||
| 2018 | $3.30 | $1.35 | $0.00 | ||
| 2019 | $4.00 | $25.78 | |||
| 2020 | $9.74 | ||||
| 2021 | $2.54 | ||||
| 2022 | $1.69 | ||||
| 2023 | $3.06 | ||||
| 2024 | $5.77 |
AI valuation
Our deep-learning model estimates DiaMedica Therapeutics Inc.'s (DMAC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $6.18
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DMAC | DiaMedica Therapeutics In… | $6.18 | 414.02M | — | — | — | — | -9.54 | 5.73 | — | -7.11 | — | 5.73 | 0.00% | — | — | -53.27% | 1178.75% | -48.64% | 0.01 | — | 8.28 | 8.23 | 0.10 | 0.00% | — | 1786.00% | -9.48% | -4.10 | 976.41% | 0.00% | 0.00% | 0.00% | -7.10 | -8.57 | — | 19.75 |
| ALT | Altimmune, Inc. | $4.31 | 380.39M | +632% | -46% | — | +2,482% | -4.16 | 3.20 | 19774.45 | -2.80 | — | 3.20 | 100.00% | -515860.00% | -475295.00% | -59.86% | 2117.00% | -54.33% | 0.01 | -11463.56 | 13.11 | 12.90 | 0.37 | -1928.00% | -9531.00% | 526.00% | -20.19% | -7.63 | 1638.41% | 0.00% | 0.00% | 0.00% | -2.57 | -3.32 | 13263.95 | 8.03 |
| ANNX | Annexon, Inc. | $5.60 | 669.73M | — | — | — | — | -2.74 | 1.29 | — | -0.71 | — | 1.29 | 0.00% | — | — | -50.84% | -955.34% | -42.67% | 0.10 | — | 10.37 | 10.23 | 0.15 | -4294.00% | — | -273.00% | -31.12% | -3.87 | -731.80% | 0.00% | 0.00% | 0.00% | -0.62 | -0.82 | — | 0.68 |
| DBVT | DBV Technologies S.A. | $20.99 | 502.12M | -17% | — | — | — | -0.71 | 2.93 | — | -0.50 | -1.28 | 2.94 | 0.00% | — | — | -135.96% | -2872.45% | -91.63% | 0.28 | — | 1.43 | 1.38 | 0.22 | 5526.00% | -10000.00% | 3297.00% | -132.98% | -3.36 | -2637.08% | 0.00% | 0.00% | 0.06% | -0.46 | -0.52 | — | -10.66 |
| DRTS | Alpha Tau Medical Ltd. | $7.76 | 661.65M | — | — | — | — | -6.09 | 3.09 | — | -4.83 | -85.26 | 3.09 | 0.00% | — | — | -43.16% | -228.37% | -32.80% | 0.20 | -104.77 | 7.40 | 6.91 | 0.04 | 714.00% | — | -960.00% | -11.39% | -2.28 | -139.53% | 0.00% | 0.00% | 0.93% | -4.06 | -6.64 | — | 1.93 |
| DSGN | Design Therapeutics, Inc. | $10.44 | 594.7M | — | — | — | — | -5.61 | 1.15 | — | -0.72 | — | 1.15 | 0.00% | — | — | -19.08% | 5921.50% | -18.31% | 0.01 | — | 29.31 | 29.16 | 0.41 | -2605.00% | — | -2613.00% | -15.60% | -5.09 | 4123.87% | 0.00% | 0.00% | 0.75% | -0.57 | -0.81 | — | 15.77 |
| ENGN | enGene Holdings Inc. | $10.11 | 517.58M | — | — | — | — | -3.84 | 2.69 | — | -2.53 | -6.75 | 2.69 | 0.00% | — | — | -53.28% | -379.44% | -44.05% | 0.19 | -41.14 | 6.30 | 6.13 | 0.16 | 5685.00% | — | 10470.00% | -22.37% | -3.10 | -310.30% | 0.00% | 0.00% | 0.00% | -2.34 | -2.86 | — | 1.76 |
| GALT | Galectin Therapeutics Inc… | $2.98 | 192.13M | — | — | — | — | -2.15 | -0.98 | — | -4.63 | -79.38 | -0.98 | 0.00% | — | — | 57.62% | 325.92% | -205.92% | -1.03 | -7.66 | 0.49 | 0.43 | -2.20 | 270.00% | — | 2670.00% | -41.38% | -1.18 | 320.80% | 0.09% | -0.20% | 0.09% | -4.53 | -4.60 | — | -40.88 |
| GNLX | Genelux Corporation | $2.98 | 112.1M | +972% | — | — | +2,543% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| KRRO | Korro Bio, Inc. | $12.13 | 114.23M | — | -2% | — | — | -2.38 | 1.24 | 87.71 | -1.33 | — | 1.24 | 100.00% | -4047.12% | -3680.36% | -50.61% | -158.39% | -37.32% | 0.28 | — | 8.79 | 8.54 | 0.12 | -8235.00% | — | 380.00% | -39.15% | -4.02 | -134.38% | 0.00% | 0.00% | 0.00% | -1.28 | -1.51 | 51.90 | -0.55 |
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- CEO
- Dietrich John Pauls
- Employees
- 27
- Beta
- 1.08
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $6.18) − 1 = — (DCF, example).